Skip to content
An Initiative of AVAC
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By
Multiple filters can be used at once

Showing results 1 - 10 of 357

Selected Filters:
13 January 2025

Characterizing Populations Prioritized for PrEP in 19 African Countries: A review of national guidance

This article from Journal of the International AIDS Society describes the results of a review of PrEP guidelines in 19 African countries to characterize which populations are prioritized for PrEP in Africa.

Research, Service Delivery

External Link
6 January 2025

Disparities in PrEP Use and Unmet Need across PEPFAR-Supported Programs: Doubling down on prevention to put people first and end AIDS as a public health threat by 2030

This article from Frontiers in Reproductive Health analyses 2023 Monitoring, Evaluation, and Reporting (MER) results from 48 PEPFAR-supported countries to calculate PrEP-to-need ratios (PnR) by geography and population to show where PrEP need is and is not being met.

Monitoring & Evaluation, Research, Service Delivery

External Link
16 December 2024

Understanding the Drivers of CAB PrEP Uptake and Use among Women in sub-Saharan Africa to Build Demand for New PrEP Methods

This article from Current HIV/AIDS Reports reviews facilitators and barriers to use of injectable cabotegravir (CAB) for PrEP by women in sub-Saharan Africa.

Demand Creation/Marketing, Research, Service Delivery

External Link
4 December 2024

I Am More Than HIV Prevention: Results from the HPTN 091 study with transgender women

HPTN 091, the I Am study, evaluated the impact of a multicomponent HIV prevention strategy to increase the uptake and adherence of pre-exposure prophylaxis (PrEP) among transgender women. The strategy included HIV prevention services, gender-affirming hormone therapy, and peer health navigation. This webinar will feature Dr. Tonia Poteat, Ph.D., Duke University School of Nursing, Division…

Research

Event
3 December 2024

Gears of Lenacapavir for PrEP Rollout

This report provides a framework for accelerated and equitable introduction of injectable lenacapavir (LEN) for PrEP, including outlining priority actions for different stakeholder groups.

Community/Advocacy, Financing & Costing, Research, Service Delivery

Document
29 November 2024

Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons

This article from the New England Journal of Medicine describes the results of PURPOSE 2, the Phase III clinical trial for injectable lenacapavir for PrEP, carried out amongst gay and bisexual men who have sex with men, trans men, trans women, and gender non binary individuals in Argentina, Brazil, Mexico, Peru, South Africa, Thailand, and…

Research

External Link
28 November 2024

Catalyzing Progress in the Inclusion of Pregnant and Lactating People in HIV Prevention Research

This satellite session from HIVR4P 2024 provided a comprehensive overview of progress on inclusion of pregnant and lactating people (PLP) in HIV prevention research since a Think Tank on PLP inclusion hosted by AVAC and PHASES in 2022, emphasizing strides in advocacy and research.

Community/Advocacy, Research

External Link
22 November 2024

Pre-Exposure Prophylaxis Implementation Gaps among People Vulnerable to HIV Acquisition: A cross-sectional analysis in two communities in western Kenya, 2021–2023

This article, from Journal of the International AIDS Society, examines PrEP awareness, uptake, and persistence among participants enrolling into an HIV incidence cohort in Kenya.

Research

External Link
15 November 2024

Update on Injectable Lenacapavir for PrEP

Please join AVAC for updates on the PURPOSE trials for injectable lenacapavir for PrEP. Gilead will provide an overview of the PURPOSE 1 and 2 trial results as well as insight into the status of PURPOSE 3, 4, and 5.

Research

Event
14 November 2024

From Clinical Trial Efficacy to Public Health Impact: A plan for accelerating access to injectable lenacapavir for PrEP

This plan provides a comprehensive view of all the moving parts for lenacapavir for PrEP introduction and identifies priority actions and actors responsible for ensuring time is not wasted and opportunity not squandered.

Financing & Costing, Monitoring & Evaluation, Normative Guidance/Policies, Research, Service Delivery

Document